HC Wainwright Reaffirms “Neutral” Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)

Verrica Pharmaceuticals (NASDAQ:VRCA)‘s stock had its “neutral” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. HC Wainwright also issued estimates for Verrica Pharmaceuticals’ FY2028 earnings at $0.11 EPS and FY2029 earnings at $0.18 EPS.

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, March 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $9.50.

Verrica Pharmaceuticals Stock Performance

Shares of VRCA opened at $0.46 on Tuesday. Verrica Pharmaceuticals has a 52-week low of $0.38 and a 52-week high of $11.41. The stock’s 50-day simple moving average is $0.60 and its 200 day simple moving average is $0.88. The stock has a market capitalization of $42.48 million, a price-to-earnings ratio of -0.25 and a beta of 1.68.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.01. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $1.30 million. On average, research analysts forecast that Verrica Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Invesco Ltd. purchased a new stake in shares of Verrica Pharmaceuticals during the 4th quarter valued at $32,000. Barclays PLC increased its stake in Verrica Pharmaceuticals by 404.6% in the third quarter. Barclays PLC now owns 31,341 shares of the company’s stock valued at $45,000 after acquiring an additional 25,130 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in Verrica Pharmaceuticals during the third quarter valued at about $87,000. Verition Fund Management LLC purchased a new stake in Verrica Pharmaceuticals during the third quarter valued at about $89,000. Finally, Jane Street Group LLC boosted its holdings in shares of Verrica Pharmaceuticals by 106.5% in the 3rd quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock worth $101,000 after purchasing an additional 36,028 shares in the last quarter. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.